Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders

Annu Rev Med. 2023 Oct 12. doi: 10.1146/annurev-med-050522-033924. Online ahead of print.ABSTRACTOpioid use disorder continues to drive overdose deaths in many countries, including the United States. Illicit fentanyl and its analogues have emerged as key contributors to the complications and mortality associated with opioid use disorder. Medications for opioid use disorder treatment, such as methadone and buprenorphine, are safe and substantially reduce opioid use, infectious complications, and mortality risk, but remain underutilized. Polysubstance use and emerging substances such as xylazine and designer benzodiazepines create additional treatment challenges. Recent clinical and policy innovations in treatment delivery, including telemedicine, bridge clinics, and expanded models for accessing methadone have the potential to increase access to life-saving care for people living with opioid use disorder. Expected final online publication date for the Annual Review of Medicine, Volume 75 is January 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.PMID:37827194 | DOI:10.1146/annurev-med-050522-033924
Source: Annual Review of Medicine - Category: General Medicine Authors: Source Type: research